Term
NSCLC
T: 8cm
N: ipsilat. hilar
M: x
Stage? |
|
Definition
T: 8cm 3 (>7cm)
N: ipsilat. hilar 1
M: x
IIIA |
|
|
Term
NSCLC
T: inv pleura
N: ipsilat. mediast
M: x
stage? |
|
Definition
NSCLC
T: inv pleura T3
N: ipsilat. mediast N2
M: x
IIIA |
|
|
Term
NSCLC
T: inv mediast
N: ipsilat. mediast
M: x |
|
Definition
NSCLC
T: inv mediast T4
N: ipsilat. mediast N2
M: x
IIIB |
|
|
Term
NSCLC
T: 2.5cm
N: supraclav
M: x
stage? |
|
Definition
NSCLC
T: 2.5cm T1
N: supraclav/contralat N3
M: x
IIIB |
|
|
Term
NSCLC
T:x
N:x
M:1
EGFR mut: +
Tx:? |
|
Definition
- if EGFR mutation (a/w improved prognosis):
- EGFR tyrosine kinase inhibitor (TKI, eg, erlotinib) first-line Rx (Lancet 2008;372:1809; NEJM 2010;362:2380 & 2011;364:947)
|
|
|
Term
NSCLC
T:x
N:x
M:1
ALK rearrengement: +
Tx:? |
|
Definition
- if ALK rearrangement:
- ALK TKI (eg, crizotinib) first-line Rx (Lancet Oncol 2011;12:1004)
|
|
|
Term
|
Definition
ca mama
- pertuzumab (anti-HER2 mAb, prevents dimerization)
- ↑ progression-free survival when added to trastuzumab as first-line Rx for metastatic dis. (NEJM 2012;366:109)
|
|
|
